Hexagon Capital Partners’s Verona Pharma VRNA Stock Holding History

Hexagon Capital Partners’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3	Closed	-$190	–	1675
2025 Q1	$190	Hold	3	–	–	﹤0.01%	1768
2024 Q4	$139	Hold	3	–	–	﹤0.01%	1798
2024 Q3	$86	Buy	+3	New	+$74	﹤0.01%	1544

Other funds holding VRNA

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Hexagon Capital Partners's VRNA Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Verona Pharma (VRNA) in Q2 2025, closing a stake of 3 shares — an estimated $190 sold.

Hexagon Capital Partners first reported a position in VRNA in Q3 2024 and held it in 3 quarters. The position peaked at $190 in Q1 2025. 292 funds tracked by Wall St. Rank hold VRNA as of Q2 2025.

Hexagon Capital Partners reported no remaining Verona Pharma position as of Q2 2025 after selling out during the quarter.
Hexagon Capital Partners sold 3 Verona Pharma shares in Q2 2025, an estimated $190.
Hexagon Capital Partners first reported a position in Verona Pharma in Q3 2024 and held it in 3 quarters.
Hexagon Capital Partners's Verona Pharma position peaked at $190 in Q1 2025.
292 funds tracked by Wall St. Rank held Verona Pharma as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.